<DOC>
	<DOCNO>NCT00899574</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy Imiquimod , Toll-like receptor 7 agonist breast cancer ( chestwall recurrence metastasis skin ) .</brief_summary>
	<brief_title>Imiquimod Breast Cancer Patients With Chest Wall Recurrence Skin Metastases</brief_title>
	<detailed_description>TLR agonists novel agent cancer therapy modify immune response . Imiquimod , synthetic TLR7 agonist proven immunomodulatory activity apply topically , lead clearance human papilloma virus ( HPV ) -induced genital wart primary skin malignancy . Its effect examine breast cancer metastatic skin . If effective , add relatively non-toxic approach treatment armamentarium patient population frequently resistant conventional therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Patients biopsyconfirmed breast cancer ( prior histological documentation acceptable ) . Patients measurable skin metastasis ( chest wall recurrence and/or nonchest wall skin metastasis eligible ) . Skin metastases suitable patient refuse definitive surgical resection radiation . ( Cohort 1 ) Concurrent systemic cancer therapy ( hormone , biologics chemotherapy ) allow distant metastasis nonprogressing ( stable respond ) regimen &gt; = 12 week skin metastasis nonresponsive ( stable progressing ) assess investigator . ( Cohort 2 ) Any concurrent systemic therapy allow Age least 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 . Patients must biopsyaccessible tumor ( skin metastasis ) agree biopsy require protocol . Patients must adequate organ bone marrow function define : absolute neutrophil count &gt; = 1,500/microliter hemoglobin &gt; = 9.5 grams/deciliter platelet &gt; = 75,000/microliter total bilirubin &lt; = 1.5 X institutional upper limit normal Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) &lt; = 2.5X institutional upper limit normal creatinine &lt; = 1.5 X institutional upper limit normal Informed consent . Brain metastases unless resect irradiated stable &gt; = 8 week . Treatment investigational agent . Patients receive radiotherapy , highpotency corticosteroid , intralesional therapy , laser therapy surgery biopsy target area within 4 week prior first dose study agent . Patients receive hyperthermia target area within 10 week prior first dose study agent . Patients uncontrolled bleed disorder . Patients therapeutically anticoagulated heparin coumadin time biopsy ( eligible anticoagulation hold prior biopsy per investigator ) . Patients aspirin platelet agent eligible . Patients known immunodeficiency receive immunosuppressive therapy . History allergic reaction imiquimod excipients . Uncontrolled intercurrent medical illness psychiatric illness/social situation would limit compliance study requirement . Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>toll-like receptor</keyword>
	<keyword>toll-like receptor agonist</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>breast cancer metastasize skin and/or chestwall</keyword>
	<keyword>immunomodulator</keyword>
</DOC>